|
Aligos Therapeutics Inc (NASDAQ: ALGS) |
|
Aligos Therapeutics Inc
ALGS's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Aligos Therapeutics Inc 's sales fell
by -60.82 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 2058
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 13.31 %
Aligos Therapeutics Inc net loss increased from $-18 millions, to $-19 millions in III. Quarter 2024,
• More on ALGS's Growth
|
|
Aligos Therapeutics Inc realized a net loss in trailing twelve months.
Aligos Therapeutics Inc realized cash reduction of $ -5.59 per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 31.83.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.57.
• More on ALGS's Valuation
|
|
|
|
|
Aligos Therapeutics Inc realized net loss in trailing twelve months.
Aligos Therapeutics Inc realized cash outflow of $ -5.59per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 31.83.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.57.
Aligos Therapeutics Inc Price to Book Ratio is at 3.81 lower than Industry Avg. of 476.72. and higher than S&P 500 Avg. of 0.01
• More on ALGS's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com